Glenmark Pharmaceuticals Inc. USA and Pfizer Inc., along with its generic-drug unit Greenstone LLC, have reached a settlement agreement to resolve price-fixing claims brought by direct purchasers of generic drugs. According to the terms of the agreement, Glenmark Pharmaceuticals will pay approximately $38 million, while Pfizer and Greenstone will pay around $33 million.
The settlement is the latest development in a long-running dispute over allegations of price-fixing in the generic drug market. The direct purchasers, who include companies that buy generic drugs directly from manufacturers, had accused several major pharmaceutical companies, including Glenmark and Pfizer, of colluding to artificially inflate prices.
By settling the claims, Glenmark and Pfizer are able to avoid the uncertainty and potential risks associated with litigating the matter in court. The settlement agreement is expected to bring closure to the dispute and provide compensation to the direct purchasers who were affected by the alleged price-fixing scheme.
The case highlights the ongoing scrutiny of the pharmaceutical industry, particularly with regards to the pricing of generic drugs. Generics are copycat versions of brand-name drugs that are designed to be more affordable, but some manufacturers have been accused of exploiting their market power to drive up prices.
Law360, a leading source of legal news and analysis, has been closely following the case and providing updates on the latest developments. With its comprehensive coverage of the pharmaceutical industry and antitrust law, Law360 is an essential resource for professionals who need to stay up-to-date on the latest trends and developments.
In addition to its daily news coverage, Law360 offers a range of features, including expert analysis, mobile apps, and advanced search functionality. Subscribers can access a vast archive of articles, as well as real-time alerts and judge information. With a free 7-day trial, readers can experience the benefits of Law360’s comprehensive coverage and expert analysis for themselves.